Infographic. Clients in opioid agonist treatment
Publication date
Description
This resource is part of the European Drug Report 2023, the EMCDDA's annual overview of the drug situation in Europe.
Trends in the number of opioid agonist clients are based on 25 countries. Only countries with data for at least 10 of the 12 years are included in the trends graph. Missing values are interpolated from adjacent years. Data for age distribution are based on 15 countries. Data for gender are based on 14 countries. Data for treatment duration are based on 7 countries.
Source data
The data used to generate infographics and charts on this page may be found below.
List of tables
- Table 1 (Coverage of opioid agonist treatment in 2021 or the most recent year and 2011/12)
- Table 2a (Clients in opioid agonist treatment)
- Table 2b (Trends in the number in opioid agonist treatment)
- Table 3 (Number of European countries implementing opioid agonist treatment, up to 2022)
Year | Series | Country | Low | Estimate | High |
---|---|---|---|---|---|
2017 | 2021 or most recent | Latvia | 8 | 10 | 12 |
2020 | 2021 or most recent | Romania | 8 | 10 | 13 |
2016 | 2021 or most recent | Lithuania | 9 | 15 | 21 |
2021 | 2021 or most recent | Cyprus | 10 | 17 | 25 |
2014 | 2021 or most recent | Poland | 16 | 21 | 28 |
2021 | 2021 or most recent | Slovakia | 14 | 23 | 32 |
2016 | 2021 or most recent | Denmark | 16 | 27 | 39 |
2016 | 2021 or most recent | Germany | 48 | 49 | 49 |
2015 | 2021 or most recent | Croatia | 39 | 50 | 62 |
2021 | 2021 or most recent | Austria | 50 | 52 | 54 |
2019 | 2021 or most recent | Ireland | 49 | 53 | 54 |
2021 | 2021 or most recent | Czechia | 57 | 59 | 61 |
2018 | 2021 or most recent | Portugal | 42 | 64 | 98 |
2019 | 2021 or most recent | Belgium | 72 | ||
2021 | 2021 or most recent | Slovenia | 69 | 75 | 80 |
2020 | 2021 or most recent | France | 78 | 80 | 82 |
2021 | 2021 or most recent | Greece | 56 | 85 | 100 |
2013 | 2021 or most recent | Norway | 56 | 86 | 100 |
2019 | 2021 or most recent | Luxembourg | 86 | ||
2020 | 2021 or most recent | Malta | 77 | 89 | 95 |
2020 | 2021 or most recent | Spain | 65 | 90 | 100 |
2012 | Previous estimate | Latvia | 4 | 5 | 7 |
2016 | Previous estimate | Romania | 5 | 7 | 9 |
2007 | Previous estimate | Lithuania | 7 | 7 | 7 |
2011 | Previous estimate | Cyprus | 25 | 31 | 37 |
2009 | Previous estimate | Poland | 10 | 13 | 19 |
2018 | Previous estimate | Slovakia | 11 | 20 | 28 |
Previous estimate | |||||
Previous estimate | |||||
Previous estimate | |||||
2011 | Previous estimate | Austria | 54 | 55 | 57 |
2011 | Previous estimate | Ireland | 44 | 53 | 57 |
2011 | Previous estimate | Czechia | 46 | 48 | 51 |
2012 | Previous estimate | Portugal | 66 | 75 | 88 |
Previous estimate | |||||
Previous estimate | |||||
Previous estimate | |||||
2011 | Previous estimate | Greece | 30 | 33 | 37 |
Previous estimate | |||||
Previous estimate | |||||
Previous estimate | |||||
2010 | Previous estimate | Spain | 82 | 96 | 100 |
Characteristic | Number in treatment | Data | Unit |
---|---|---|---|
Number in treatment | EU | 511210 | number |
Number in treatment | EU+2 | 523821 | number |
Age | <15 | 0 | % |
Age | 15-19 | 0 | % |
Age | 20-24 | 2 | % |
Age | 25-29 | 5 | % |
Age | 30-34 | 11 | % |
Age | 35-39 | 17 | % |
Age | 40-44 | 20 | % |
Age | 45-49 | 16 | % |
Age | 50-54 | 15 | % |
Age | 55-59 | 7 | % |
Age | 60-64 | 5 | % |
Age | >64 | 1 | % |
Gender | Females | 23 | % |
Gender | Males | 77 | % |
Medication | Methadone | 55.88 | % |
Medication | Buprenorphine | 34.57 | % |
Medication | Other | 6.73 | % |
Medication | Slow-release oral morphine | 2.56 | % |
Medication | Diacetylmorphine | 0.24 | % |
Medication | Dihydrocodeine | 0.02 | % |
Duration | <12 | 10 | % |
Duration | 12 to 24 | 11 | % |
Duration | 25 to 60 | 27 | % |
Duration | 61 to 120 | 21 | % |
Duration | >120 | 30 | % |
Country | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Spain | 82372 | 76263 | 69111 | 61954 | 61859 | 59264 | 58749 | 58857 | 58447 | 58540 | 55058 | 55058 |
Germany | 77400 | 76200 | 75400 | 77300 | 77500 | 77200 | 78500 | 78800 | 79400 | 79700 | 81300 | 81300 |
Other countries | 110244 | 113180 | 111533 | 104996 | 106186 | 106951 | 106194 | 107576 | 108587 | 109814 | 110117 | 111228 |
France | 155944 | 170322 | 172795 | 176065 | 174274 | 178313 | 178560 | 177490 | 177100 | 178700 | 178800 | 180000 |
Year | Buprenorphine/naloxone combination | Heroin assisted treatment (including pilots) | High-dosage buprenorphine treatment | Methadone maintenance treatment | Opioid agonist treatment in prison | Slow-release morphine |
---|---|---|---|---|---|---|
1967 | 1 | |||||
1968 | 2 | |||||
1969 | ||||||
1970 | 3 | |||||
1971 | ||||||
1972 | ||||||
1973 | ||||||
1974 | 4 | |||||
1975 | 5 | |||||
1976 | ||||||
1977 | 6 | |||||
1978 | ||||||
1979 | ||||||
1980 | ||||||
1981 | ||||||
1982 | ||||||
1983 | ||||||
1984 | ||||||
1985 | 1 | |||||
1986 | ||||||
1987 | 8 | 2 | ||||
1988 | 3 | |||||
1989 | 9 | |||||
1990 | 11 | 4 | ||||
1991 | 12 | |||||
1992 | 15 | 6 | ||||
1993 | 16 | |||||
1994 | 17 | |||||
1995 | 20 | 9 | ||||
1996 | 1 | 22 | ||||
1997 | 2 | 23 | ||||
1998 | 1 | 3 | 26 | 10 | 1 | |
1999 | 8 | 11 | ||||
2000 | 10 | 14 | ||||
2001 | 11 | 27 | 15 | |||
2002 | 14 | |||||
2003 | 3 | 15 | ||||
2004 | 1 | 16 | 16 | |||
2005 | 18 | 3 | ||||
2006 | 4 | 19 | 19 | 5 | ||
2007 | 7 | 20 | ||||
2008 | 13 | 4 | 23 | |||
2009 | 16 | |||||
2010 | 24 | |||||
2011 | 5 | |||||
2012 | 17 | 25 | ||||
2013 | ||||||
2014 | 26 | |||||
2015 | ||||||
2016 | ||||||
2017 | ||||||
2018 | ||||||
2019 | 18 | |||||
2020 | ||||||
2021 | ||||||
2022 | 18 | 5 | 20 | 27 | 26 | 5 |
Hidden tables for page
ID | Term |
---|---|
10 | WHO target |
20 | Recent/penultimate |
30 | Number in treatment |
40 | Gender breakdown (percent) |
50 | Trends in the number in opioid agonist treatment |
60 | Age distribution |
70 | Type of medication |
80 | Treatment duration (months) |
90 | Number of countries |
Originally published in
European Drug Report 2023: Trends and Developments
Main subject
Target audience
Type
Copyright status
- Creative Commons Attribution 4.0 International (CC BY 4.0)
Related assets in the Media library
Previous slide
Next slide